Aspiro Pharma's Ketorolac Tromethamine Injection Recalled Nationwide by FDA Due to Glass Particulates
Aspiro Pharma Limited has initiated a nationwide Class II recall for multiple lots of Ketorolac Tromethamine Injection, USP, due to glass particulate matter. This action, impacting a critical pain management drug, necessitates immediate supply chain review for procurement directors and regulatory heads. The recall highlights persistent quality control challenges in sterile injectables, demanding enhanced supplier qualification and vigilance for business continuity.
FDA Class II Recall: Aspiro Pharma's Ketorolac Tromethamine Injection Impacted by Glass Particulates
Aspiro Pharma Limited, based in Telangana, India, has initiated a voluntary Class II recall of multiple lots of its Ketorolac Tromethamine Injection, USP, distributed nationwide in the United States. The U.S. Food and Drug Administration (FDA) classified this action as D-0036-2026, stemming from the confirmed presence of particulate matter, specifically identified as glass, within the injectable product. This recall affects Ketorolac Tromethamine Injection, USP, 60 mg/2 mL (30 mg/mL), 2 mL Single-Dose Vials, intended for intramuscular use. The product is manufactured by Aspiro Pharma Limited for Camber Pharmaceuticals, Inc., located in Piscataway, NJ 08854. For procurement directors, this event necessitates an immediate assessment of inventory levels and current demand for Ketorolac Tromethamine. The affected lots include AS1240347A (Exp Date 09/2026), AS1240144A (Exp Date 05/2026), AS1240145A and AS1240146A (Exp Date 06/2026), and AS1250295A (Exp Date 05/2027). Regulatory affairs heads must review existing quality agreements with both Aspiro Pharma Limited and Camber Pharmaceuticals, Inc., to understand accountability and ensure compliance with recall procedures. Supply chain VPs should recognize the potential for supply disruption for this critical pain management medication and evaluate the resilience of their sourcing strategies for sterile injectables from international manufacturers.
Aspiro Pharma's Manufacturing Facility in India: A Key Sterile Injectable Supplier
The recalled Ketorolac Tromethamine Injection, USP, originates from Aspiro Pharma Limited's manufacturing facility located at Survey No. 321, Biotech Park, Phase III, Karkapatla Village, Markook (Mandal), Siddipet (District), Telangana - 502281, India. This site serves as a significant production hub for injectable pharmaceuticals, supplying products like Ketorolac Tromethamine to global markets, including the United States via distributors such as Camber Pharmaceuticals, Inc. The presence of glass particulate matter in a sterile injectable product raises serious concerns regarding the facility's adherence to Good Manufacturing Practices (GMP) and its quality control systems, particularly in aseptic processing and container closure integrity. For procurement directors, this incident underscores the imperative for enhanced due diligence and on-site audits of international manufacturing partners, especially those producing sterile products. Regulatory affairs teams must ensure that their supplier qualification programs are robust enough to identify and mitigate such quality risks before products reach the market. Business development executives should evaluate the long-term strategic implications of relying on single-source suppliers in regions where regulatory oversight, while evolving, may present unique challenges. This event highlights the need for continuous monitoring of manufacturing quality at all points in the supply chain.
Supply Chain Vulnerabilities for Ketorolac Tromethamine Users in the U.S.
The nationwide distribution of Aspiro Pharma Limited's Ketorolac Tromethamine Injection, USP, through Camber Pharmaceuticals, Inc., means that a broad segment of the U.S. healthcare system is exposed to this recall. Ketorolac Tromethamine is a widely used nonsteroidal anti-inflammatory drug (NSAID) prescribed for the short-term management of moderate to severe acute pain, often administered in hospital and clinical settings. The recall of multiple lots due to glass particulate matter directly impacts the availability and safety of this essential medication. Procurement teams and hospital pharmacies that have sourced this product from Camber Pharmaceuticals, Inc. must immediately identify and quarantine affected lots, initiating reverse logistics processes. Regulatory affairs departments are now tasked with managing potential drug shortage communications and ensuring patient safety protocols are in place, as particulate matter in injectables can lead to serious adverse events. Supply chain VPs should view this recall as a critical indicator of potential vulnerabilities within their pharmaceutical supply networks, prompting a strategic re-evaluation of supplier diversity and geographic sourcing to build greater resilience against future disruptions for critical injectable medications.
Strategic Sourcing: Identifying Alternative Ketorolac Tromethamine Suppliers
Given the Class II recall of Aspiro Pharma Limited's Ketorolac Tromethamine Injection, USP, procurement directors must urgently identify and qualify alternative suppliers to mitigate supply chain disruptions. While specific alternative suppliers are not detailed in the provided intelligence, the market for Ketorolac Tromethamine, a generic injectable, typically includes multiple manufacturers. However, qualifying new sterile injectable suppliers, particularly for the U.S. market, involves stringent regulatory hurdles and significant lead times for facility audits, analytical testing, and potential FDA approvals. For regulatory affairs heads, expediting the qualification process for new manufacturing sites and ensuring their compliance with FDA GMP standards for sterile products is paramount. This includes rigorous review of quality systems, batch records, and stability data. Business development executives should explore strategic partnerships or licensing opportunities with other established pharmaceutical manufacturers known for their robust quality systems and track record in sterile injectables. Geographic diversity in sourcing is a key consideration to reduce reliance on any single region or facility, thereby enhancing supply chain resilience and ensuring continuous access to essential medications like Ketorolac Tromethamine.
Aspiro Pharma Limited's Regulatory Compliance: Implications of the Current Recall
While the provided intelligence does not detail a history of prior FDA Warning Letters or Import Alerts specifically for Aspiro Pharma Limited, this Class II recall for glass particulate matter in Ketorolac Tromethamine Injection, USP, represents a significant regulatory event. The FDA's classification indicates that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote, but the issue is serious enough to warrant a nationwide recall. This incident will undoubtedly trigger heightened scrutiny from the FDA on Aspiro Pharma's manufacturing processes, particularly those related to sterile product filling and visual inspection. For regulatory affairs and quality assurance teams, this recall necessitates a thorough root cause analysis by Aspiro Pharma and the implementation of robust corrective and preventive actions (CAPAs). Companies like Camber Pharmaceuticals, Inc., which distribute Aspiro Pharma's products, must closely monitor these remediation efforts and maintain transparent communication with the FDA. This event serves as a critical data point for re-evaluating supplier risk profiles, emphasizing that even without a prior history of enforcement actions, a single significant quality lapse can severely impact business continuity and market reputation. Future FDA inspections of Aspiro Pharma's facility will likely focus intensely on sterile manufacturing controls and foreign material exclusion protocols.